ProfileGDS5678 / 1453843_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 39% 39% 39% 39% 38% 38% 39% 39% 39% 39% 39% 39% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9303439
GSM967853U87-EV human glioblastoma xenograft - Control 22.8953639
GSM967854U87-EV human glioblastoma xenograft - Control 32.88539
GSM967855U87-EV human glioblastoma xenograft - Control 42.8385339
GSM967856U87-EV human glioblastoma xenograft - Control 52.8417739
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9588238
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9273438
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.876239
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8644939
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.886839
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8837139
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8641239
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8905939
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8899239